Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 473 of 6351
-
New combo therapy aims to control advanced lung cancer
Disease control Recruiting nowThis is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the safety and tolerability of YL201 in combination wi…
Phase 1/2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Stroke patients may get faster lifesaving care by skipping standard scans
Disease control Not yet recruitingThe investigators initiated a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) controlled trial to evaluate the efficacy and safety of the direct transfer to angiography suite (DTAS) triage strategy compared to the conventional triage strategy with CT/MR…
Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for seniors with aggressive lymphoma: Four-Drug cocktail aims to spare chemo
Disease control Recruiting nowThis is a prospective, single-center, open-label, single-arm clinical study designed to evaluate the efficacy and safety of Pola-ZR-Glo (Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Glofitamab) regimen in older treatment-naive patients with large B-cell lymphoma.
Phase 2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug duo aims to shrink lung tumors before surgery
Disease control Recruiting nowThe aim of the study to evaluate the safety and efficacy of Sacituzumab Tirumotecan in combination with osimertinib for neoadjuvant treatment in patients with resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer.
Phase 2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug duo takes on deadly brain infection
Disease control Not yet recruitingAlpE is a novel drug combination under development for the treatment of TB, with several positive attributes for TBM, including rapid bactericidal activity. The current trial aims to assess the plasma and CSF PK, as well as the safety and tolerability of alpibectir and three dose…
Phase 2 • Sponsor: BioVersys AG • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Rechallenge therapy shows promise for Tough-to-Treat colorectal cancer
Disease control Not yet recruitingThis study is a phase II, open-label, multicenter clinical trial designed to evaluate two different treatment options for patients with metastatic colorectal cancer whose disease has progressed after standard therapies. The study compares a rechallenge treatment using irinotecan …
Phase 2 • Sponsor: Gruppo Oncologico Italia Meridionale • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New cancer drug BNT3214 enters human trials for advanced tumors
Disease control Recruiting nowThis study is the first time the drug BNT3214 (also referred to as PM8102) will be tested in people. It is designed to find out if the drug is safe and how well it works for adults with advanced solid tumors. The study will have three parts. The first two parts (Parts A and B) wi…
Phase 1/2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can zapping the main tumor boost survival in advanced lung cancer?
Disease control Not yet recruitingFor patients with non-small cell lung cancer and more than five metastatic lesions (non-oligometastatic disease), does radical treatment of the primary lung lesion, in addition to pharmacotherapy, also provide benefits in terms of progression-free survival (PFS) and local control…
Sponsor: Guizhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Cord blood stem cells aim to repair hearts after attack
Disease control Not yet recruitingThis trial is a Phase II, multicenter clinical study. The purpose of this trial is to evaluate the safety and efficacy of MiSaver, a cellular therapy product, in patients who have experienced an acute myocardial infarction (AMI). Specifically, the study aims to assess the improve…
Phase 2 • Sponsor: HONYA Medical Co Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo therapy aims to keep leukemia away after transplant
Disease control Not yet recruitingThe goal of this clinical trial is to learn if Asciminib, a first in class allosteric inhibitor, as a add-on maintenance therapy can provides benefits and further prevents relapse in post allogenic hematopoietic stem-cell transplant (HSCT) of patients with Philadelphia chromosome…
Phase 2 • Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New triple therapy aims to stall return of ovarian cancer
Disease control Not yet recruitingEfficacy and safety of Benmelstobart combined with Anlotinib and oral metronomic Cyclophosphamide in the treatment of recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (BACON study) in China
Phase 2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo aims to boost immune attack on tough lung cancer
Disease control Recruiting nowEligible untreated participants with Extensive Stage Small Cell Lung Cancer (ES-SCLC) who are ≥ 18 years of age will be randomized to receive ivonescimab 10 milligrams per kilogram (mg/kg) or ivonescimab 20 mg/kg in combination with carboplatin and etoposide. Ivonescimab is a ty…
Phase 2 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Gene therapy breakthrough targets kidney disease in High-Risk patients
Disease control Recruiting nowThe purpose of the study is to evaluate safety, tolerability, and preliminary effectiveness following administration of PS-002 in adults with primary Immunoglobulin A (IgA) nephropathy. This will be a first-in-human study and will include participants at high risk of disease prog…
Phase 1/2 • Sponsor: Purespring Therapeutics Limited • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
Heat-and-freeze therapy plus immunotherapy aims to turn liver tumors into cancer-fighting vaccines
Disease control Recruiting nowThis study focuses on the treatment of liver metastases from three common cancers: colorectal cancer, triple-negative breast cancer and melanoma. Currently, there are limitations in the treatment of liver metastases of these cancers. Multimodal thermophysical ablation therapy can…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Can a Four-Drug cocktail tame pancreatic cancer? a Real-World trial seeks answers
Disease control Recruiting nowThis is multicenter, prospective, open label, non-interventional study that will collect real-world data (RWD) on the clinical efficacy and safety of NalIriFOx as a first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
Sponsor: Hellenic Cooperative Oncology Group • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a targeted drug boost standard ovarian cancer therapy?
Disease control Recruiting nowThe goal of this clinical study is to learn more about the safety, tolerability, and preliminary effectiveness of TUB-040 when given in combination with standard ovarian cancer treatments in participants with high-grade epithelial serous or endometrioid ovarian cancer. This stud…
Phase 1/2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New HIV vaccine trial aims to boost immune control in patients on ART
Vaccine Recruiting nowThe goal of this randomized clinical trial is to evaluate the safety and immunogenicity of the HIV Therapeutic DNA Vaccine (ICVAX) in participants with HIV-1 infection under antiretroviral therapy (ART). The study compares three delivery methods - Teresa -EPT I, PharmaJet Tropis,…
Phase 1 • Sponsor: Immuno Cure Holding (HK) Limited • Aim: Vaccine
Last updated Jun 27, 2026 12:07 UTC
-
New drug combo targets Hard-to-Treat lung cancer
Disease control Not yet recruitingTo explore the efficacy and safety of vebreltinib plus platinum-doublet chemotherapy as first-line therapy in patients with driver gene-negative, locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET overexpression.
Phase 2 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New eye drug tiespectus takes on aflibercept in major wet AMD trial
Disease control Recruiting nowResearchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called M…
Phase 2/3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can short bursts of hard exercise ease bronchiectasis?
Disease control Recruiting nowThe aim of our study is to investigate the effect of high-intensity interval exercise (HIIE) on the symptoms of bronchiectasis in patients with the disease. The main questions it aims to answer are: 1. Does HIIE improve respiratory function in patients with bronchiectasis? 2. Do…
Sponsor: Saglik Bilimleri Universitesi • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC